Tumescent Contravenom Solution for Snakebite Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current first aid measures for snakebites are ineffective, expensive, and inaccessible in remote areas, with antivenom requiring refrigeration, medical expertise, and posing risks of serious side effects, while existing treatments fail to address the need for a safe, inexpensive, and simple pre-hospital solution to delay and reduce venom toxicity and tissue necrosis.
Innovation Solution
The development of a tumescent contravenom solution comprising a vasoconstrictor, physiological crystalloid solution, and contravenom agents like Varespladib, which is administered subcutaneously or intramuscularly near the envenomation site, diluting venom and neutralizing its toxic effects, and can be self-administered by non-medical personnel.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antivenom is used for snakebite treatment, then venom neutralization is achieved, but the treatment becomes expensive, requires refrigeration, and needs medical expertise
Solution Approach 1:
The patent divides the treatment into two components: a stable contravenom drug (Varespladib) that can be stored at room temperature, and a tumescent solution vehicle that provides both delivery and local anesthesia. This segmentation allows the therapeutic agent to be separated from the complex refrigerated antivenom products while maintaining effectiveness.
Solution Approach 2:
The tumescent solution acts as an intermediary vehicle that delivers the contravenom drug to the bite site while providing additional benefits (local anesthesia, vasoconstriction) that enhance the therapeutic effect and reduce pain, making the treatment more acceptable and easier to administer.
2Reliability
If intravenous antivenom infusion is administered, then systemic venom neutralization occurs, but the procedure requires trained medical personnel and carries risk of serious side effects
Solution Approach 1:
The patent enables self-administration of the contravenom solution at the bite site, eliminating the need for trained medical personnel to perform intravenous infusions. The solution can be injected directly into the affected area by the victim or bystanders, making the treatment accessible in remote areas without medical infrastructure.
Solution Approach 2:
The contravenom drug is administered directly at the bite site before venom can be absorbed into the systemic circulation, preventing toxicity before it occurs rather than treating it after systemic absorption. This preliminary local action simplifies the procedure and eliminates the need for complex IV access and monitoring.
3Object-affected harmful factors
If first aid measures focus on delaying venom absorption, then systemic toxicity is reduced, but the measures are rudimentary and dependent on provider effectiveness
Solution Approach 1:
The patent changes the key parameter from merely delaying absorption (physical restriction) to actively neutralizing venom chemically at the bite site. The tumescent solution delivers high concentrations of contravenom directly where venom enters, ensuring neutralization regardless of absorption rate or provider skill level.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively delays and reduces systemic and local toxicity, is inexpensive, stable at room temperature, and can be administered in remote areas, providing immediate pain relief and prolonged local anesthesia, thereby improving survival chances and reducing complications from snakebites.
Implementation Method 1
a vasoconstrictor
Implementation Method 2
providing immediate pain relief and prolonged local anesthesia
Data Source
AI summary
A tumescent contravenom solution including: (a) a vasoconstrictor, (b) a physiological crystalloid solution, and (c) optionally a contravenom agent that neutralizes tissue toxic enzymes present in a venom and/or a drug that impairs or paralyzes lymphatic smooth muscle function and impairs lymphatic transport of venom. Also described are methods of treating an envenomation in a subject, and a kit for performing the method of treating an envenomation.